研究单位：[1]BeiGene[2]West China Hospital of Sichuan University Chengdu,Sichuan,China[3]Cancer Hospital Chinese Academy of Medical Sciences Beijing,Beijing,China,100021[4]Beijing Cancer Hospital Beijing,Beijing,China,100142[5]Fujian Cancer Hospital Fuzhou,Fujian,China,350014[6]First Affiliated Hospital of Xiamen University Xiamen,Fujian,China,361003[7]The First Affiliated Hospital of Xinxiang Medical University Xinxiang,Henan,China,453100[8]Henan Cancer Hospital Zhengzhou,Henan,China,450008[9]Union Hospital of Tongji Medical College,Huazhong University of Science and Technology Wuhan,Hubei,China,430023[10]Sichuan Cancer hospital Chengdu,Sichuan,China,610041
研究目的：
This is a phase 3,randomized,double-blind,placebo-controlled study to compare the efficacy and safety of BGB-A317 versus P placebo with chemoradiotherapy in participants with Localized Esophageal Squamous Cell Carcinoma.
